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ABSTRACT
Objectives: To assess the prevalence and severity of
ultrasonographic abnormalities of the hand and wrist
of asymptomatic patients with systemic lupus
erythematosus (SLE) and compare these findings with
those from patients with SLE with musculoskeletal
signs or symptoms and healthy controls.
Methods: We conducted a prospective cross-
sectional study that evaluated bilaterally, with grey-
scale and power Doppler (PD) ultrasound (US), the
dorsal hand (2nd to 5th metacarpophalangeal and 2nd
to 5th proximal interphalangeal joints) and wrist
(radiocarpal, ulnocarpal and intercarpal joints) of
30 asymptomatic patients with SLE, 6 symptomatic
patients with SLE and 10 controls. Synovial
hypertrophy (SH) and intra-articular PD signal were
scored using semiquantitative grading scales (0–3).
Individual scores were graded as normal (SH≤1 and
PD=0) or abnormal (SH≥2 or PD≥1). Global indexes
for SH and PD were also calculated. US findings were
correlated with clinical and laboratory data and disease
activity indexes.
Results: US detected SH (score ≥1) in 77%
asymptomatic patients with SLE, mostly graded as
minimal (score 1: 63%). 23% of the asymptomatic
patients with SLE showed abnormal US PD findings
(SH≥2 or PD≥1). SH was present in all symptomatic
patients with SLE, mostly graded as moderate (grade
2: 67%), and with associated PD signal (83%). SH
(score 1) was identified in 50% of controls, however,
none presented abnormal US PD findings. SH index in
the asymptomatic SLE group was higher than in the
control group (2.0 (0–5) vs 0.5 (0–2), median (range),
p=0.01) and lower than in the symptomatic SLE group
(7.0 (4–23), median (range), p<0.001). No significant
correlation was demonstrated between US PD findings
and clinical or laboratory variables and disease activity
indexes.
Conclusion: A small subgroup of asymptomatic
patients with SLE may present subclinical joint
inflammation. Global US scores and PD signal may be
important in disease evaluation and therapeutic
monitoring.
INTRODUCTION
Joint involvement is one of the most
common features of systemic lupus erythema-
tosus (SLE), with up to 95% of patients
experiencing arthralgia or arthritis during
the course of their disease.1 While multiple
joints can be affected, nearly 50% of patients
report difﬁculties in daily life performance
due to hand symptoms.2 Traditionally, SLE
arthritis is considered to be mild, reversible
and non-erosive, with only 5–15% of cases
progressing to deforming arthropathy, either
erosive—as in rhupus syndrome (an overlap
of SLE with rheumatoid arthritis (RA))—or
non-erosive—as in Jaccoud’s arthropathy.3 4
In routine clinical practice, joint involvement
is usually assessed with physical examination
and radiographical studies. However, this
approach has been shown to have a low sen-
sitivity for joint abnormalities when com-
pared with ultrasound (US) evaluation or
MRI, suggesting that the burden of joint
inﬂammation may be underestimated in the
current clinical practice.5 The value of US
with power Doppler (PD) in inﬂammatory
arthritis has been extensively demonstrated
in the literature, with similar sensitivity and
speciﬁcity in the detection of synovitis in
comparison with MRI, with the advantage of
being more accessible and less expensive.6–8
While US shows the morphology of the syn-
ovial membrane, PD identiﬁes increased vas-
cularisation within it, allowing for the
detection of active joint inﬂammation.9 It is
known that in RA synovial abnormalities are
present before clinically evident arthritis
develops, and that early treatment can limit
erosive changes and avoid disease progres-
sion.10 In this context, US PD has nowadays
an established role in the detection of
subclinical joint inﬂammation in RA, namely
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to predict progression in patients with clinical
remission.11 12
Although there is evidence that US PD is a valuable
technique in the evaluation of musculoskeletal symp-
toms in SLE, the prevalence of subclinical joint abnor-
malities in SLE remains to be deﬁned.13 14 Furthermore,
while it is known that minimal synovial proliferation may
be seen in up to 50% of healthy subjects, the distinction
between ‘normal’ synovial hypertrophy (SH) and patho-
logical subclinical synovitis in SLE still requires clariﬁca-
tion.15–18
The aim of this study was to assess the prevalence and
precise grading of US abnormalities of the hand and
wrist in asymptomatic patients with SLE, while compar-
ing these ﬁndings with a group of patients with SLE with
musculoskeletal signs or symptoms and with healthy
controls.
PATIENTS AND METHODS
Patients and study design
We conducted a prospective cross-sectional study which
included patients fulﬁlling the 1997 revised American
College of Rheumatology (ACR) criteria for SLE,19
under standard of care, and on stable medication in the
preceding 4 weeks. Patients were sequentially recruited
from the population of the two outpatient autoimmune
disease units from Centro Hospitalar de Lisboa Central
(Lisbon, Portugal) between January 2014 and July 2015.
A subset of these patients has been previously charac-
terised.20 We excluded patients with a known diagnosis
of rhupus syndrome (deﬁned as patients with SLE also
satisfying the classiﬁcation criteria for RA)21 or Jaccoud’s
arthropathy and mild deforming arthropathy (according
to the Jaccoud’s Arthropathy Index),4 22 as well as
patients with known osteoarthritis, trauma or surgery of
the hand or wrist. Healthy controls had no personal or
familiar history of autoimmune diseases and denied pre-
vious hand or wrist trauma and osteoarthritis. The study
was approved by the Hospital Centre Ethics Committee
and performed according to the principles of good clin-
ical practice and to the Declaration of Helsinki.
Informed consent was obtained from all enrolled
patients.
Clinical and laboratory evaluation
Patients with SLE underwent a medical interview from
which demographic, clinical data and previous history
were recorded, together with a detailed physical examin-
ation according to the European League Against
Rheumatism (EULAR) recommendations.23 Patients
were then classiﬁed as asymptomatic (if musculoskeletal
symptoms or signs were absent) and symptomatic (if
musculoskeletal signs or symptoms were present).
Disease activity was assessed using the SLE Disease
Activity Index (SLEDAI-2K),24 and organ damage was
assessed using the ACR/Systemic Lupus International
Collaborating Clinics (SLICC) score.25 Active disease was
deﬁned as a SLEDAI score equal or superior to 3.26
Anti-nuclear antibodies (ANA) were detected by indirect
immunoﬂuorescence using HEp-2 epithelial cells as the
substrate (American Type Culture Collection CCL 23).
The serum dilution was 1/160, and a titre equal to or
greater than 1:160 was considered positive. Serum
samples were diluted 1/10 for detection of antibodies
against double-stranded DNA (anti-dsDNA) on Crithidia
luciliae. Positive results were quantiﬁed by ELISA for
IgG. Laboratory evaluation also included erythrocyte
sedimentation rate, C3 and C4 complement levels by
nephelometry and ELISA for rheumatoid factor (RF)
and anti-citrullinated protein IgG antibodies (anti-CCP).
Grey-scale and PD ultrasonography
Patients and controls underwent bilateral musculoskel-
etal US examination with PD evaluation of the hand and
wrist, performed on the same week as the medical inter-
view. All US scans were performed simultaneously by two
radiologists with experience in musculoskeletal radi-
ology, blinded to clinical and laboratory data, using a
Logiq E9 machine (General Electric Medical Systems,
Milwaukee, USA) with a 6–15 MHz linear array probe
operating at 15 MHz. PD evaluation was performed with
a PD frequency of 10 MHz, gain 50% and low wall
ﬁlter.27 For each US evaluation, an adequate amount of
warm gel was used, and compression with the probe was
avoided, to accurately evaluate synovial vascularisation.
US examinations were performed with comparable tech-
nical and environmental factors. Using a multiplanar
scanning technique according to EULAR guidelines for
musculoskeletal US in rheumatology,28 the following
joints were scanned bilaterally, on the dorsal side: radio-
carpal, ulnocarpal, intercarpal; 2nd–5th metacarpopha-
langeal (MCP) and 2nd–5th proximal interphalangeal
(PIP) joints (total of 22 joints per person). The ﬁrst
MCP and interphalangeal joints were not scanned to
avoid the bias of possible coexisting osteoarthritis.
SH was deﬁned as hypoechoic intra-articular tissue
that was non-displaceable and poorly compressible and
which may or may not exhibit PD signal, according to
deﬁnitions provided by the Outcome Measures in RA
Clinical Trials (OMERACT) Special Interest Group for
Musculoskeletal US in Rheumatology.29 Synovial vascu-
larisation was assessed with PD evaluation. Each joint was
evaluated individually and classiﬁed for SH and
intra-articular PD using two semi-quantitative grading
methods, the Szkudlarek grading method,30 and the
OMERACT–EULAR composite PDUS synovitis score
(ﬁgure 1).31 The Szkudlarek method grades each par-
ameter individually as follows: SH: 0—no synovial thick-
ening, 1—minimal synovial thickening (ﬁlling the angle
between the periarticular bones, without bulging over
the line linking tops of the bones), 2—synovial thicken-
ing bulging over the line linking tops of the periarticular
bones but without extension along the bone diaphysis,
3—synovial thickening bulging over the line linking tops
of the periarticular bones and with extension to at least
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one of the bone diaphysis; PD: 0—no ﬂow in the syno-
vium, 1—single vessel signals, 2—conﬂuent vessel signals
in less than half of the area of the synovium, 3—vessel
signals in more than half of the area of the synovium.30
The OMERACT–EULAR composite PDUS synovitis
score is a composite score of synovial hyperplasia and
PD signal: 0 (normal joint)—no grey-scale-detected syn-
ovial hyperplasia and no PD signal; 1 (minimal synovitis)
—grade 1 synovial hyperplasia and ≤ grade 1 PD signal;
2 (moderate synovitis)—grade 2 synovial hyperplasia and
≤ grade 2 PD signal; or grade 1 synovial hyperplasia and
grade 2 PD signal; 3 (severe synovitis)—grade 3 synovial
hyperplasia and ≤ grade 3 PD signal, or grade 1 or 2 syn-
ovial hyperplasia and grade 3 PD signal.31 A reference
atlas for grey-scale and PD semi-quantitative scoring of
RA joints was also consulted for the purpose of grading
abnormalities in the radiocarpal, ulnocarpal or intercar-
pal joints.32 To compare the groups of patients with SLE
and controls, individual scores of SH and PD were
dichotomised: SH scores of 0 and 1 and PD score 0 were
considered normal; SH scores 2 and 3 and PD scores
1–3 were considered pathological.30 33 Decisions of indi-
vidual joint scores were made by consensus between the
two radiologists.
For the purpose of group comparisons, in addition to
individual scores, we also calculated two global indexes
for SH and PD, corresponding to the sum of individual
scores for all joints assessed. SH index and PD index
were calculated using the Szkudlarek grading
method,14 34 and the Global OMERACT–EULAR
Synovitis Score (GLOESS) was calculated using the com-
posite PDUS synovitis score.31
Statistical analysis and sample size
Continuous variables were recorded as medians (range
or IQR) and comparisons were made using Wilcoxon
rank sum test. Dichotomous variables were examined by
frequency distribution, recorded as proportions, and
comparisons were made using the χ2 test or Fisher’s
exact test. Correlations between variables were analysed
with Spearman’s correlation coefﬁcient or with simple
logistic regression, as appropriate. Nominal two-sided
Figure 1 Representative ultrasound images of patients with SLE. Images (A–D) show dorsal longitudinal scans of the
radiocarpal joint with different degrees of synovial hypertrophy and PD, according to the Szkudlarek semi-quantitative grading
method: (A) no synovial hypertrophy (grade 0); (B) minimal synovial hypertrophy (grade 1) with minimal PD signal (grade 1); (C)
moderate synovial hypertrophy (grade 2) with minimal PD signal (grade 1); (D) severe synovial hypertrophy (grade 3) with
moderate PD signal (grade 2). Images (E and F) show dorsal longitudinal scans of the metacarpophalangeal joints: (E) absence
of synovial hypertrophy (grade 0); (F) severe synovial hypertrophy (grade 3) with minimal PD signal (grade 1). In these
examples, the OMERACT–EULAR composite PDUS synovitis scores were equivalent to the synovial hypertrophy scores from
the Szkudlarek method. EULAR, European League against Rheumatism; PD, power Doppler; OMERACT, Outcome Measures in
RA Clinical Trials; SLE, systemic lupus erythematosus.
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p values of<0.05 were considered statistically signiﬁcant.
Analyses were performed using STATA Statistical Software
Release 13 (College Station, Texas, USA).
Based on data from Yoon et al (subclinical synovitis
detected in 58.3% of asymptomatic patients with SLE and
5.6% of controls),14 for a 0.05 α-value and 90% power,
and considering a 3:1 ratio, a sample size of 30 asymptom-
atic patients with SLE and 10 controls was calculated.
RESULTS
Population characterisation
Thirty-six consecutive patients with SLE (34 females, 2
males) were enrolled in this study, with a median age of
41.5 years (IQR=35–53). Age and gender in the controls
(n=10) were similar to those of the patients with SLE
(median age: 33.5 years (IQR=29–49), p=0.2; female
gender: 9 (90%), p=0.61).
The majority of patients with SLE (n=30, 83.3%) were
asymptomatic, while the remaining six presented muscu-
loskeletal signs or symptoms at enrolment. Demographic,
clinical, laboratory and therapeutic features were homo-
genous between the two groups (table 1).
All patients with SLE were positive for ANA,
anti-dsDNA was present in 17 (47.2%), 3 (8.3%) were
RF positive and 1 (2.8%) was anti-CCP positive. All
patients with SLE have been treated with hydroxychloro-
quine during the course of their disease. Of these, 19
asymptomatic (63.3%) and 4 symptomatic (66.7%)
patients were receiving oral prednisolone at the time of
enrolment (median dose 5 mg, range 2.5–25 mg in the
asymptomatic group; median dose 5 mg, range 3.75–
10 mg in the symptomatic group; p=0.93).
Ultrasonographical findings
US findings at joint level
When considering the total number of joints examined,
US detected a signiﬁcantly higher prevalence of joints
with SH (grade ≥1) in the SLE population, when com-
pared with the control group (11.1% (88/792) vs 2.7%
(6/220), p<0.001) (table 2).
In the asymptomatic SLE group, the prevalence of joints
with SH (grade ≥1) was also signiﬁcantly higher than in the
control group (8.2% (54/660) vs 2.7% (6/220), p=0.005)
and signiﬁcantly lower than in the symptomatic patients
with SLE (8.2% (54/660) vs 25.7% (34/132), p<0.001).
The prevalence of abnormal SH (score ≥2) and posi-
tive PD signal in the asymptomatic SLE population was
0.7% (5/660) and 1.4% (9/660), respectively. None of
these ﬁndings were identiﬁed in the joints of the
healthy controls.
US findings at population level
US detected SH (grade ≥1) in 29 of the 36 (80.6%)
patients with SLE, and particularly in 23 of the 30
(76.7%) asymptomatic patients with SLE (table 3).
In the asymptomatic SLE group, most SH was
graded as minimal (grade 1: 19 out of 30 patients,
63.3%). Abnormal US PD ﬁndings (SH ≥2 or PD
signal ≥1) were seen in 7 (23.3%) asymptomatic
patients with SLE.
In the symptomatic SLE group, SH was present in all
the patients, and mostly graded as moderate (grade 2: 4
out of 6, 66.7%). PD signal was present in 5 out of 6
patients (83.3%).
SH (grade ≥1) was identiﬁed in 5 out of 10 healthy
controls (50%), however none presented abnormal SH
(score ≥2) or a positive PD signal.
The SH index in the asymptomatic SLE group was
higher than in the control group (2.0 (0–5) vs 0.5 (0–2),
median (range), p=0.01) and lower than in the symp-
tomatic SLE group (2.0 (0–5) vs 7.0 (4–23), median
(range), p<0.001). GLOESS was equivalent to the SH
index in asymptomatic patients with SLE and in the
control group, being slightly higher than the SH index
in the symptomatic patients with SLE (7.5 (4–23),
median (range)).
PD index was higher in the symptomatic patients with
SLE when compared with the asymptomatic patients
with SLE (4.0 (0–8) vs 0 (0–3), median (range),
p=<0.001) and to the controls (4.0 (0–8) vs 0 (0–0),
median (range), p=0.001).
Clinical and laboratory associations with US findings
No correlation was demonstrated on univariate analysis
between US PD variables (GLOESS, SH index, PD
index, prevalence of abnormal US PD ﬁndings) and
demographic, clinical and laboratory data (see online
supplementary table SI). Disease activity and organ
damage scores did not show signiﬁcant correlation with
US PD variables (see online supplementary tables SI
and SII). Patients receiving oral prednisolone at the
time of the evaluation had higher PD indexes compared
with patients who were not taking this medication (see
online supplementary table SIII).
DISCUSSION
The present study provides data on the US PD ﬁndings
of a population of patients with SLE without musculosk-
leletal signs or symptoms, in comparison with symptom-
atic patients with SLE and healthy controls. In our study,
US revealed SH of the hand or wrist in 8% of the exam-
ined joints and in 77% of patients with SLE who denied
arthralgia and did not present abnormalities on physical
examination. The majority of these patients presented
minimal SH (score 1) without associated PD, which
could be considered normal, according to previous lit-
erature.13 30 33 However, abnormal US ﬁndings (SH≥2
or PD signal) were seen in 23% of patients. We believe
that these ﬁndings indicate subclinical joint inﬂamma-
tion. Accordingly, while minimal SH was detected in
50% of the controls, none presented abnormal SH
(score≥2) or positive PD signal.
While a number of studies have recently described US
ﬁndings in the SLE population, only some of these
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included patients who did not complain of musculoskel-
etal symptoms at the time of the US evaluation,5 35–39
and, to our knowledge, only one focused on asymptom-
atic patients.14 In these studies, the prevalence of US
abnormalities in asymptomatic patients with SLE varied
from 3% to 58%.5 13 36–38 This inconsistency is thought
to be related to US reporting methodologies, mostly due
to the lack of consensus about the deﬁnition of a posi-
tive US examination. Most studies deﬁned synovitis as
SH grade 1 or higher; however, grade 1 synovitis without
PD can be found in healthy subjects and in patients with
osteoarthritis.13 33 In addition, while the majority of
studies described a semi-quantitative grading score in
the methodology, results were most often presented as
binary (synovitis/no synovitis), and the prevalence of
each SH score was usually not addressed.13 Furthermore,
to our knowledge, only a limited number of studies
described global US scores in patients with SLE.14 39
Our study contributes to a better understanding of
subclinical joint disease in patients with SLE, as it pro-
vides a detailed description of the US PD ﬁndings both
at joint level and at population level and characterises
Table 1 Demographical, clinical, laboratory and therapeutic characteristics of asymptomatic and symptomatic patients with
SLE
Asymptomatic (n=30) Symptomatic (n=6) p Value
Age, years, median (IQR) 41.5 (35–52) 45 (34–58) 0.54
Gender (female), n (%) 28 (93.3) 6 (100.0) 0.51
Disease duration, years, median (IQR) 9 (6–13) 12.5 (10–17) 0.29
Nr ACR criteria, median (IQR) 6 (4–7) 6.5 (6–7) 0.30
Auto-antibodies
ANA positivity, n (%) 30 (100.0) 6 (100.0) –
RF positivity, n (%) 2 (6.7) 1 (16.7) 0.43
Anti-CCP positivity, n (%) 1 (3.3) 0 (0) 1.00
Disease activity markers
Anti-dsDNA positivity, n (%) 13 (43.3) 4 (66.7) 0.39
C3 (decreased), n (%) 12 (40.0) 2 (33.3) 1.00
C4 (decreased), n (%) 4 (13.3) 0 (0) 1.00
ESR (increased), n (%) 15 (50.0) 2 (33.3) 0.66
Disease activity and organ damage scores
SLEDAI, median (IQR) 2 (0–4) 2 (0–8) 0.96
SLICC, median (IQR) 0 (0–1) 0.5 (0–1) 0.71
Cumulative medication, n (%)
Hydroxychloroquine 30 (100.0) 6 (100.0) –
Prednisolone 23 (76.7) 4 (66.7) 0.63
Azathioprine 16 (53.3) 4 (66.7) 0.67
Mycophenolate mofetil 6 (20.0) 1 (16.7) 1.00
Cyclophosphamide 6 (20.0) 0 (0) 0.56
Rituximab 1 (3.3) 0 (0) 1.00
Current medication, n (%)
Hydroxychloroquine 24 (80.0) 6 (100.0) 0.56
Prednisolone 19 (63.3) 4 (66.7) 1.00
Azathioprine 12 (40.0) 3 (50.0) 0.67
Mycophenolate mofetil 5 (16.7) 1 (16.7) 1.00
Methotrexate 2 (6.7) 2 (33.3) 0.12
Statistical tests: Wilcoxon rank sum test, χ2 test, Fisher’s exact test.
ANA, anti-nuclear antibodies; Anti-CCP, anti-citrullinated protein antibody; C3, C3 complement fraction; C4, C4 complement fraction; ds-DNA,
anti-double-stranded DNA antibody; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor antibody; SLEDAI, SLE Disease Activity
Index; SLICC, Systemic Lupus International Collaborating Clinics.
Table 2 Number of joints with SH and PD signal in each group








p ValueNumber of joints
(n=220) (n=792) (n=660) (n=132)
A B C D
SH≥1, n (%) 6 (2.7) 88 (11.1) 54 (8.2) 34 (25.7) <0.001 0.005 <0.001 <0.001
SH≥2, n (%) 0 25 (3.1) 5 (0.7) 20 (15.1) 0.002 0.23 <0.001 <0.001
PD≥1, n (%) 0 26 (3.3) 9 (1.4) 17 (12.9) 0.002 0.07 <0.001 <0.001
Statistical tests: χ2 test, Fisher’s exact test.
PD, power Doppler; SH, synovial hypertrophy; SLE, systemic lupus erythematosus.
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the groups of patients and controls by using two sets of
global US scores. SH index and GLOESS scores were
similar in the asymptomatic SLE group; however, in the
symptomatic group GLOESS values were slightly higher.
We believe GLOESS may be advantageous, as it includes
information about SH and PD signal in the same score.
Although the prevalence of asymptomatic patients with
SLE with SH did not reach statistical signiﬁcance in com-
parison to healthy controls, both SH index and GLOESS
were signiﬁcantly higher in the asymptomatic SLE popu-
lation when compared with the control group.
Altogether, these ﬁndings encourage the use of global
US scores for a more detailed joint evaluation in SLE, in
clinical practice and in future trials.
Compared with the study of Yoon et al,14 our study
detected a higher prevalence of SH (grade≥1) in asymp-
tomatic patients with SLE. While the previous study
identiﬁed joint effusion and/or SH in 58% of asymp-
tomatic patients with SLE, we detected SH (grade ≥1)
in 77% asymptomatic patients with SLE. This may be
due to the larger number of joints examined in our
study (22 joints per patient, in comparison with 3 joint
recesses in the previous study—wrist, 2nd and 3rd MCP)
and to the higher frequency of our linear array probe
(15 MHz, in comparison to 10 MHz in the previous
study). However, while the previous study classiﬁed these
58% of patients as having subclinical synovitis, only 23%
of the asymptomatic patients with SLE in our study were
classiﬁed as having subclinical joint inﬂammation.
In our study, patients with abnormal US PD ﬁndings
did not show signiﬁcant differences regarding demo-
graphic, clinical and laboratory data when compared
with those with normal US PD ﬁndings. In addition, no
signiﬁcant correlation was found between US PD vari-
ables and disease activity or organ damage scores. This is
in agreement with several previous studies, suggesting
that global assessment of patients with SLE should be
complemented by imaging modalities, such as
US.35 37 39 Interestingly, patients under treatment with
oral prednisolone had higher PD indexes. In addition,
the prevalence of PD signal and PD indexes were signiﬁ-
cantly higher in the symptomatic patients with SLE
when compared with the asymptomatic patients and
controls, suggesting that PD signal could be considered
a marker for active musculoskeletal disease.36
The most important limitations of our study are the
moderate sample size (which may limit generalisability)
and the high prevalence of steroid use among the SLE
population (which could reduce the global inﬂamma-
tory burden and result in lower prevalence and grading
of the US PD ﬁndings). Furthermore, intake of non-
steroidal anti-inﬂammatory drugs at the time of US
imaging, a potential confounder in US PD evaluation,
was not accounted for. Although US-detected subclinical
joint abnormalities have been previously associated with
the development of musculoskeletal symptoms, the prog-
nostic value of these ﬁndings remains to be determined.
Larger longitudinal studies are required to conﬁrm the
signiﬁcance of subclinical US PD ﬁndings, speciﬁcally
regarding the predictive value for the development of
long-term joint damage.13 40
In conclusion, a small subgroup of patients with SLE
without artralgia or clinical evidence of arthritis may
present subclinical joint inﬂammation. Global US scores
and PD signal may be important in disease evaluation
and therapeutical monitoring.














(n=10) (n=36) (n=30) (n=6)
A B C D
SH grades
1–3, n (%) 5 (50) 29 (80.6) 23 (76.7) 6 (100) 0.07 0.11 0.058 0.19
1, n (%) 5 (50) 20 (55.6) 19 (63.3) 1 (16.7) 0.5 0.35 0.215 0.049
2, n (%) 0 8 (22.2) 4 (13.3) 4 (66.7) 0.12 0.30 0.008 0.014
3, n (%) 0 1 (2.8) 0 1 (16.7) 0.78 - 0.375 0.167
PD grades
1–3, n (%) 0 11 (30.6) 6 (20) 5 (83.3) 0.045 0.15 0.001 0.006
1, n (%) 0 6 (16.7) 5 (16.7) 1 (16.7) 0.21 0.22 0.375 0.695
2, n (%) 0 4 (11.1) 1 (3.3) 3 (50) 0.36 0.75 0.036 0.01
3, n (%) 0 1 (2.8) 0 1 (16.7) 0.78 – 0.375 0.167
Abnormal US PD findings
SH≥2 or PD≥1, n (%) 0 12 (33.3) 7 (23.3) 5 (83.3) 0.04 0.16 0.001 0.01
SH and PD index; GLOESS
SH index, median (IQR) 0.5 (0–1) 2 (1–4) 2.0 (1–3) 7.0 (5–9) 0.003 0.01 <0.001 <0.001
PD index, median (IQR) 0 (0–0) 0 (0–1) 0 (0–0) 4.0 (2–6) 0.05 0.13 0.001 <0.001
GLOESS, median (IQR) 0.5 (0–1) 2 (1–4) 2.0 (1–3) 7.5 (5–10) 0.003 0.01 <0.001 <0.001
Abnormal US PD findings were defined as presence of SH≥2 or PD signal≥1. Statistical tests: Wilcoxon rank sum test, χ2 test, Fisher’s exact
test.
GLOESS, Global OMERACT–EULAR Synovitis Score; PD, power Doppler; SH, synovial hypertrophy; SLE, systemic lupus erythematosus;
US, ultrasound.
6 Ruano CA, Malheiro R, Oliveira JF, et al. Lupus Science & Medicine 2017;3:e000184. doi:10.1136/lupus-2016-000184
Lupus Science & Medicine
group.bmj.com on January 19, 2017 - Published by http://lupus.bmj.com/Downloaded from 
Author affiliations
1Radiology Department, Hospital de Santo António dos Capuchos, Centro
Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal
2Autoimmune Disease Unit, Unidade de Doenças Auto-imunes/Serviço
Medicina 3, Hospital de Santo António dos Capuchos, CHLC, Lisbon, Portugal
3Núcleo de Estudos de Doenças Auto-imunes da Sociedade Portuguesa de
Medicina Interna (NEDAI/SPMI), Lisbon, Portugal
4Autoimmune Disease Unit, Unidade de Doenças Auto-imunes/Serviço
Medicina 7.2, Hospital Curry Cabral, CHLC, Lisbon, Portugal
Contributors All persons who meet authorship criteria are listed as authors,
and all authors certify that they have made substantial contributions to the
work to take public responsibility for the content. Each author agrees to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately investigated
and resolved. Furthermore, each author certifies that this material or similar
material has not been and will not be submitted to or published in any other
publication. Specific contributions made by each author: Category 1 –
Conception and design of study: CAR, SP, LSV, MFMF: Acquisition of data:
CAR, RMo, JFO, SP, LSV, MFMF: Analysis and/or interpretation of data: CAR,
MFM-F. Category 2 – Drafting the manuscript: CAR MFMF – Revising the
manuscript critically for important intellectual content: CAR, RM, JFO, SP,
LSV, MFM-F. Category 3 – Approval of the version of the manuscript to be
published: CAR, RM, JFO, SP, LSV, MFM-F.
Competing interests None declared.
Patient consent Obtained.
Ethics approval All procedures performed were in accordance with the ethical
standards of the Institutional Ethics Committee ((Comissão de Ética do Centro
Hospitalar de Lisboa Central; approval number 1115 (2014)) and with the
1964 Helsinki declaration and its later amendments or comparable ethical
standards.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Grossman JM. Lupus arthritis. Best Pr Res Clin Rheumatol
2009;23:495–506.
2. Malcus Johnsson P, Sandqvist G, Bengtsson A, et al. Hand function
and performance of daily activities in systemic lupus erythematosus.
Arthritis Rheum 2008;59:1432–8.
3. Ball EM, Bell AL. Lupus arthritis-do we have a clinically useful
classification? Rheumatology (Oxford) 2012;51:771–9.
4. van Vugt RM, Derksen RH, Kater L, et al. Deforming arthropathy or
lupus and rhupus hands in systemic lupus erythematosus.
Ann Rheum Dis 1998;57:540–4.
5. Mosca M, Tani C, Carli L, et al. The role of imaging in the evaluation
of joint involvement in 102 consecutive patients with systemic lupus
erythematosus. Autoimmun Rev 2015;14:10–15.
6. Kane D, Grassi W, Sturrock R, et al. Musculoskeletal ultrasound—A
state of the art review in rheumatology. Part 2: Clinical indications for
musculoskeletal ultrasound in rheumatology. Rheumatology (Oxford)
2004;43:829–38.
7. Szkudlarek M, Court-Payen M, Strandberg C, et al. Power Doppler
ultrasonography for assessment of synovitis in the
metacarpophalangeal joints of patients with rheumatoid arthritis:
a comparison with dynamic magnetic resonance imaging. Arthritis
Rheum 2001;44:2018–23.
8. Terslev L, Torp-Pedersen S, Savnik A, et al. Doppler ultrasound and
magnetic resonance imaging of synovial inflammation of the hand in
rheumatoid arthritis: a comparative study. Arthritis Rheum
2003;48:2434–41.
9. Iagnocco A, Epis O, Delle Sedie A, et al. Ultrasound imaging for the
rheumatologist XVII. Role of colour Doppler and power Doppler. Clin
Exp Rheumatol 2008;26:759–62.
10. Marcusa DP, Mandl LA. Challenges in imaging in preclinical
rheumatoid arthritis. Rheum Dis Clin North Am 2014;40:727–34.
11. Bresnihan B, Kane D. Sonography and subclinical synovitis.
Ann Rheum Dis 2004;63:333–4.
12. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR
recommendations for the use of imaging of the joints in the clinical
management of rheumatoid arthritis. Ann Rheum Dis
2013;72:804–14.
13. Zayat AS, Md Yusof MY, Wakefield RJ, et al. The role of ultrasound
in assessing musculoskeletal symptoms of systemic lupus
erythematosus: a systematic literature review. Rheumatology
(Oxford) 2016;55:485–94.
14. Yoon HS, Kim KJ, Baek IW, et al. Ultrasonography is useful to
detect subclinical synovitis in SLE patients without musculoskeletal
involvement before symptoms appear. Clin Rheumatol
2014;33:341–8.
15. Ejbjerg B, Narvestad E, Rostrup E, et al. Magnetic resonance
imaging of wrist and finger joints in healthy subjects occasionally
shows changes resembling erosions and synovitis as seen in
rheumatoid arthritis. Arthritis Rheum 2004;50:1097–106.
16. Parodi M, Silvestri E, Garlaschi G, et al. How normal are the hands
of normal controls? A study with dedicated magnetic resonance
imaging. Clin Exp Rheumatol 2006;24:134–41.
17. Mangnus L, Schoones JW, van der Helm-van Mil AH. What is the
prevalence of MRI-detected inflammation and erosions in small
joints in the general population? A collation and analysis of
published data. RMD Open 2015;1:e000005.
18. Padovano I, Costantino F, Breban M, et al. Prevalence of ultrasound
synovial inflammatory findings in healthy subjects. Ann Rheum Dis
2016;75:1819–23.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the
classification of systemic lupus erythrematosus. Arthritis Rheum
1982;25:1271–7.
20. Moraes-Fontes MF, Lúcio I, Santos C, et al. Neuropsychiatric
features of a cohort of patients with systemic lupus erythematosus.
ISRN Rheumatol 2012;2012:989218.
21. Panush RS, Lawrence N, Longley S, et al. ‘Rhupus’ Syndrome.
Arch Intern Med 1988;148:1633–6.
22. Alarcon-Segovia D, Abud-Mendoza C, Diaz-Jouanen E, et al.
Deforming arthropathy of the hands in systemic lupus
erythematosus. J Rheumatol 1988;15:65–9.
23. Grunke M, Antoni CE, Kavanaugh A, et al. Standardization of joint
examination technique leads to a significant decrease in variability
among different examiners. J Rheumatol 2010;37:860–4.
24. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult
systemic lupus erythematosus: updated version of British Isles
Lupus Assessment Group (BILAG 2004), European Consensus
Lupus Activity Measurements (ECLAM), Systemic Lupus Activity
Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire
for Population Studies (SLAQ), Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2 K), and Systemic Lupus
International Collaborating Clinics/American College of
Rheumatology Damage Index (SDI). Arthritis Care Res 2011;63
(Suppl. 11):S37–46.
25. Gladman D, Ginzler E, Goldsmith C, et al. The development and
initial validation of the systemic lupus international
collaborating clinics/American College of Rheumatology Damage
Index for Systemic Lupus Erythematosus. Arthritis Rheum
1996;39:363–9.
26. Yee CS, Farewell VT, Isenberg DA, et al. The use of systemic lupus
erythematosus disease activity index-2000 to define active disease
and minimal clinically meaningful change based on data from a large
cohort of systemic lupus erythematosus patients. Rheumatology
(Oxford) 2011;50:982–8.
27. Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in
colour/power Doppler ultrasound in rheumatology. Ann Rheum Dis
2008;67:143–9.
28. Backhaus M, Burmester GR, Gerber T, et al. Guidelines for
musculoskeletal ultrasound in rheumatology. Ann Rheum Dis
2001;60:641–9.
29. Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal
ultrasound including definitions for ultrasonographic pathology.
J Rheumatol 2005;32:2485–7.
30. Szkudlarek M, Court-Payen M, Jacobsen S, et al. Interobserver
agreement in ultrasonography of the finger and toe joints in
rheumatoid arthritis. Arthritis Rheum 2003;48:955–62.
31. D’Agostino MA, Wakefield RJ, Berner-Hammer H, et al. Value of
ultrasonography as a marker of early response to abatacept in
patients with rheumatoid arthritis and an inadequate response to
methotrexate: results from the APPRAISE study. Ann Rheum Dis
2016;75:1763–9.
Ruano CA, Malheiro R, Oliveira JF, et al. Lupus Science & Medicine 2017;3:e000184. doi:10.1136/lupus-2016-000184 7
Immunology and inflammation
group.bmj.com on January 19, 2017 - Published by http://lupus.bmj.com/Downloaded from 
32. Hammer HB, Bolton-King P, Bakkeheim V, et al. Examination of intra
and interrater reliability with a new ultrasonographic reference atlas
for scoring of synovitis in patients with rheumatoid arthritis.
Ann Rheum Dis 2011;70:1995–8.
33. Machado FS, Furtado RNV, Takahashi RD, et al. Sonographic cutoff
values for detection of abnormalities in small, medium and large
joints: A comparative study between patients with rheumatoid arthritis
and healthy volunteers. Ultrasound Med Biol 2015;41:989–98.
34. Filer A, de Pablo P, Allen G, et al. Utility of ultrasound joint counts in
the prediction of rheumatoid arthritis in patients with very early
synovitis. Ann Rheum Dis 2011;70:500–7.
35. Delle Sedie A, Riente L, Scirè CA, et al. Ultrasound imaging for the
rheumatologist XXIV. Sonographic evaluation of wrist and hand joint
and tendon involvement in systemic lupus erythematosus. Clin Exp
Rheumatol 2009;27:897–901.
36. Gabba A, Piga M, Vacca A, et al. Joint and tendon involvement
in systemic lupus erythematosus: An ultrasound study of
hands and wrists in 108 patients. Rheumatol 2012;
51:2278–85.
37. Torrente-Segarra V, Lisbona MP, Rotés-Sala D, et al. Hand
and wrist arthralgia in systemic lupus erythematosus is
associated to ultrasonographic abnormalities. Jt Bone Spine
2013;80:402–6.
38. Dreyer L, Jacobsen S, Juul L, et al. Ultrasonographic
abnormalities and inter-reader reliability in Danish patients with
systemic lupus erythematosus—a comparison with clinical
examination of wrist and metacarpophalangeal joints. Lupus
2015;24:712–19.
39. Iagnocco A, Ceccarelli F, Rizzo C, et al. Ultrasound evaluation of
hand, wrist and foot joint synovitis in systemic lupus erythematosus.
Rheumatol 2014;53:465–72.
40. Lins CF, Santiago MB. Ultrasound evaluation of joints in systemic
lupus erythematosus: a systematic review. Eur Radiol
2015;25:2688–92.
8 Ruano CA, Malheiro R, Oliveira JF, et al. Lupus Science & Medicine 2017;3:e000184. doi:10.1136/lupus-2016-000184
Lupus Science & Medicine
group.bmj.com on January 19, 2017 - Published by http://lupus.bmj.com/Downloaded from 
without musculoskeletal symptoms
patients with systemic lupus erythematosus
inflammation in the hands and wrists of 
Ultrasound detects subclinical joint
Vieira and Maria Francisca Moraes-Fontes
Carina A Ruano, Rui Malheiro, João F Oliveira, Sofia Pinheiro, Luís S
doi: 10.1136/lupus-2016-000184
2017 4: Lupus Sci Med 
 http://lupus.bmj.com/content/4/1/e000184




This article cites 40 articles, 19 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (6)Immunology and Inflammation
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 19, 2017 - Published by http://lupus.bmj.com/Downloaded from 
